Who makes Clindamycin 2% in hydrocortisone 1% lotion?

Clindamycin 2% in hydrocortisone 1% lotion is developed by British Columbia Cancer Agency.

What development phase is Clindamycin 2% in hydrocortisone 1% lotion in?

Clindamycin 2% in hydrocortisone 1% lotion is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Clindamycin 2% in hydrocortisone 1% lotion

British Columbia Cancer Agency · Phase 2 active Small molecule

At a glance

Generic name	Clindamycin 2% in hydrocortisone 1% lotion
Sponsor	British Columbia Cancer Agency
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Clindamycin 2% in hydrocortisone 1% lotion CI brief — competitive landscape report
Clindamycin 2% in hydrocortisone 1% lotion updates RSS · CI watch RSS
British Columbia Cancer Agency portfolio CI